Log In
BCIQ
Print this Print this
 

RDX002

  Manage Alerts
Collapse Summary General Information
Company Ardelyx Inc.
DescriptionNon-absorbed NaP2b phosphate transport inhibitor
Molecular Target Solute carrier family 34 sodium phosphate member 2 (SLC34A2) (NaPi2b)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPreclinical
Standard IndicationHyperphosphatemia
Indication DetailsTreat hyperphosphatemia in end stage renal disease (ESRD) patients
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

$198.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/03/2014

Undisclosed

Undisclosed

$198.0M

Get a free BioCentury trial today